Skip to main content

Advertisement

SpringerLink
Log in

Psychotropic medication during pregnancy and lactation

  • Review Article
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Despite the traditional notion that pregnancy is a time of joy and emotional well being, evidence suggests that it does not protect women against mental illness. Untreated mental illness carries wide-ranging repercussions for mother, child and family that often outweigh those associated with treatment. Clinical management is complex, involving competing risks to mother and offspring; the challenge lies in effectively treating mental illness, whilst minimising exposure of the child to harmful medication. The paucity of robust published evidence on which to base the principles of psychiatric care further compounds the issue. Pregnancy significantly affects plasma drug levels and immature foetal/neonatal physiology renders the child prone to damage from pharmacological agents, all of which cross the placenta/enter breast-milk to varying degrees. Risks include teratogenicity, obstetrical complications, perinatal syndromes, and long-term behavioural problems. Despite evidence that some psychotropic drugs may be safe during pregnancy, knowledge regarding the risks of antenatal exposure to medications remains far from complete. The pregnant or breastfeeding woman requires an individualised risk-benefit analysis with regard to the commencement or continuance of psychotropic medication. If treatment is deemed necessary, monotherapy at the lowest possible dose should be prescribed. More robust safety data is available for older psychotropic drugs, which should be employed in preference to newer agents with unestablished safety profiles. Pregnant/breastfeeding women should also be educated with regard to early detection of signs of drug toxicity in both themselves and their babies. Despite shared responsibility, the ultimate decision with regard to reasonable risk, and what constitutes it, rests with the informed patient. Close psychiatric monitoring and coordinated multidisciplinary care with the obstetrician and paediatrician combine with such informed patient choices to comprise the components of a holistic model of care, targeted at optimizing the complex management of women with psychiatric illness during pregnancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Miller LJ (2001) Psychiatric disorders during pregnancy. In: Stotland NL, Steward DE (eds) Psychological aspects of women’s health care: the interface between psychiatry and obstetrics and gynaecology, 2nd edn. American Psychiatric Press, Washington, pp 67–93

    Google Scholar 

  2. Cohen LS, Rosenbaum JF (1998) Psychotropic use during pregnancy: weighing the risks. J Clin Psychiatry 59(Suppl 2):18–28

    PubMed  Google Scholar 

  3. Levey L, Ragan K, Hower-Hartley A, Newport DJ, Stowe ZN (2004) Psychiatric disorders in pregnancy. Neurol Clin 22:863–893

    PubMed  Google Scholar 

  4. Duffy CL (1983) Postpartum depression: identifying women at risk. Genesis 11:21

    Google Scholar 

  5. O’Hara MW, Neunabar DJ, Zekosi EM (1984) Prospective study of postpartum depression: prevalence, course and predictive factors. J Abnorm Psychol 93:158–171

    PubMed  CAS  Google Scholar 

  6. McNeil TJ, Kaji L, Malquist-Larson A (1984) Women with non-organic psychosis: pregnancy’s effect on mental health during pregnancy. Acta Psychiatr Scand 70:127–139

    PubMed  CAS  Google Scholar 

  7. Neziroglu FN, Anemone MA, Yaryura-Tobias JA (1992) Onset of obsessive compulsive disorder in pregnancy. Am J Psychiatry 149:947–950

    PubMed  CAS  Google Scholar 

  8. Williams KE, Koran L (1997) Obsessive compulsive disorder in pregnancy, the puerperium and the premenstrum. J Clin Psychiatry 58:330–334

    PubMed  CAS  Google Scholar 

  9. Kendell RE, Chalmers JC, Platz C (1987) Epidemiology of puerperal psychosis. Br J Psychiatry 150:662–673

    PubMed  CAS  Google Scholar 

  10. Sichel DA, Cohen LS, Dimmock JA, Rosenbaum JF (1993) Postpartum obsessive compulsive disorders: a case series. J Clin Psychiatry 54:156–159

    PubMed  CAS  Google Scholar 

  11. Apfel RJ, Handel MH (1993) Madness and loss of motherhood: sexuality, reproduction and long-term mental illness. American Psychiatric Press, Washington

    Google Scholar 

  12. Sobel DE (1961) Infant mortality and malformations in children of schizophrenic women. Psychiatr Q 35:60–64

    Google Scholar 

  13. Oates M (2001) Death from psychiatric causes. In: Lewis G, Drife J (eds) Why mothers die 1997–1999. Confidential inquiries into maternal deaths in the United Kingdom. Royal College of Obstetricians and Gynaecologists Press, London, pp 165–187

    Google Scholar 

  14. Miller LJ (1997) Sexuality, reproduction and family planning in women with schizophrenia. Schizophr Bull 23:623–625

    PubMed  CAS  Google Scholar 

  15. Dickson RA, Edwards A (1997) Clozapine and fertility. Am J Psychiatry 154:582–583

    PubMed  CAS  Google Scholar 

  16. Kaplan B, Modai I, Stoler M, Kitai E, Valevski A, Weizman A (1995) Clozapine treatment and risk of unplanned pregnancy. J Am Board Fam Pract 8:239–241

    PubMed  CAS  Google Scholar 

  17. Pearson KH, Nonacs R, Cohen LS (2002) Practical guidelines for the treatment of psychiatric disorders during pregnancy. In: Pearson KH, Sonawalla SB, Rosenbaum JF (eds) Womens’ health and psychiatry. Lippincott, Williams and Wilkins, Philadelphia, pp 115–123

    Google Scholar 

  18. Orr ST, Miller CA (1995) Maternal depressive symptoms and risk of poor pregnancy outcomes: review of the literature and preliminary findings. Epidemiol Rev 17:165–171

    PubMed  CAS  Google Scholar 

  19. Murray L (1997) The impact of postnatal depression on infant development. J Child Psychol Psychiatry 77:99–101

    CAS  Google Scholar 

  20. Mehta DK (2006) British National Formulary. BMA Publishing Group Ltd, London

    Google Scholar 

  21. Langman J (1985) Human development: normal and abnormal. In: Langman J (ed) Medical embryology. Williams and Wilkins, Baltimore, pp 123

    Google Scholar 

  22. Coyle I, Wayner M, Singer G (1976) Behavioural teratogenesis: a critical evaluation. Pharmacol Biochem Behav 4:191–200

    PubMed  CAS  Google Scholar 

  23. Robertson RT, Majka JA, Peter CP, Bokelman DL (1980) Effects of prenatal exposure to chlorpromazine on postnatal development and behaviour of rats. Toxicol Appl Pharmacol 53:541–549

    PubMed  CAS  Google Scholar 

  24. Kellogg CK (1988) Benzodiazepines: influence on the developing brain. Prog Brain Res 73:207–228

    Article  PubMed  CAS  Google Scholar 

  25. Kellogg C, Ison J, Miller J (1983) Prenatal diazepam exposure: effects on auditory temporal resolution in rats. Psychopharmacology 79:332–337

    PubMed  CAS  Google Scholar 

  26. Stowe ZN, Nemeroff CB (1998) Psychopharmacology during pregnancy and lactation. In: Schatzberg AF, Nemeroff CB (eds) Textbook of psychopharmacology. American Psychiatric Press, Washington, pp 823–837

    Google Scholar 

  27. Elia J, Simpson JM (1990) Antidepressant medications during pregnancy and lactation; foetal teratogenic and toxic effects. In: Amsterdam JD (ed) Pharmacotherapy of depression: applications for the outpatient practitioner. Marcel Dekker, New York, pp 337–379

    Google Scholar 

  28. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J (1996) Pharmacological management of psychiatric illness and pregnancy: dilemmas and guidelines. Am J Psychiatry 153:592–606

    PubMed  CAS  Google Scholar 

  29. Crombie DL, Pincent RJ, Fleming D (1972) Imipramine and pregnancy. Br Med J 2:745

    Google Scholar 

  30. McElhatton PR, Garbis HM, Elefant E, Vial T, Bellemin B, Mastroiacovo P, Arnon J, Rodriguez-Pinilla E, Schaefer T, Merlob P, Dal Verme S (1996) The outcome of pregnancy in 689 women exposed to therapeutic doses of anti-depressants. A collaborative study of the European Network of Teratology Information Service. Reprod Toxicol 10:285–294

    PubMed  CAS  Google Scholar 

  31. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G (2002) Child development following exposure to tricyclic anti-depressants or fluoxetine throughout foetal life: a prospective controlled study. Am J Psychiatry 159:1889–1895

    PubMed  Google Scholar 

  32. Ward RK, Zamorski MA (2002) Benefits and risks of psychiatric medications during pregnancy. Am Fam Physician 66:629–636

    PubMed  Google Scholar 

  33. Cowe L, Lloyd D, Dawling S (1982) Neonatal convulsions caused by withdrawal from maternal clomipramine. Br Med J 284:1837–1838

    CAS  Google Scholar 

  34. Nonacs R, Cohen L (2003) Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin North Am 26:547–562

    PubMed  Google Scholar 

  35. Ericson A, Kallen B, Wilholm B (1999) Delivery outcome after the use of anti-depressants in early pregnancy. Eur J Clin Pharmacol 55:503–508

    PubMed  CAS  Google Scholar 

  36. Simon GE, Cunningham ML, Davies RL (2002) Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159:2055–2061

    PubMed  Google Scholar 

  37. Nordeng H, Lindemann R, Perminov KV, Reikvam A (2001) Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediat 90:288–291

    PubMed  CAS  Google Scholar 

  38. Goldstein DJ (1995) Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 15:417–420

    PubMed  CAS  Google Scholar 

  39. Hendrick V, Stowe Z, Altshuler LL, Hwang S, Lee E, Haynes D (2003) Placental passage of antidepressant medications. Am J Psychiatry 160:993–996

    PubMed  Google Scholar 

  40. Cohen L, Heller V, Bailey J, Grush L, Ablon JS, Bouffard SM (2000) Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 48:996–1000

    PubMed  CAS  Google Scholar 

  41. Costei A, Kozer E, Ho T, Ito S, Koren G (2002) Perinatal outcome following third trimester exposure to paroxetine. Arch Paediatr Adolesc Med 156:1129–1132

    Google Scholar 

  42. Wogelius P, Norgaard M, Munk EM (2005) Maternal use of selective serotonin reuptake inhibitors and risk of adverse pregnancy outcome. Pharmacoepidem Drug Safety 14:S72–S73. (www.mhra.gsi.gov.uk)

    Google Scholar 

  43. GlaxoSmithKline Clinical Trial Register (2005) Epidemiology Study: Updated preliminary report on Bupropion in pregnancy and the occurrence of cardiovascular and major congenital malformations. (http://www.ctr.gsk.cp.uk/Summary/paroxetine/studylist.asp)

  44. Kallen B, Otterblad A, Olausson P. Anti-depressants drugs during pregnancy and infant congenital heart defect. An English translation of this information is available on the MHRA website (www.mhra.gsi.gov.uk)

  45. Poulson E, Robson J (1964) Effect of phenelzine and some related compounds in pregnancy. J Endocrinol 30:205–215

    PubMed  CAS  Google Scholar 

  46. Kohen D (2004) Psychotropic medication in pregnancy. Adv Psychiatric Treatment 10:59–66

    Google Scholar 

  47. Einarsen A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, Mastroiacovo P, Addis A, Matsui D, Schuler L, Einarson TR, Koren G (2001) Pregnancy outcome following gestational exposure to venlafaxine: a multicentre prospective controlled study. Am J Psychiatry 158:1728–1730

    Google Scholar 

  48. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, Shakir S, Einarson A (2005) Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynaecol 192:932–936

    CAS  Google Scholar 

  49. Van Waes A, Van De Velde E (1969) Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Psychopharmacol 9:224–237

    Google Scholar 

  50. Kopelman AE, McCullar FW, Heggeness L (1975) Limb malformations following maternal use of haloperidol. JAMA 231:62–64

    Google Scholar 

  51. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S (1977) Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight and intelligence quotient score. Am J Obstet Gynaecol 128:486–488

    CAS  Google Scholar 

  52. Wisner KL, Perel JM (1988) Psychopharmacological agents and electro-convulsive therapy during pregnancy and the puerperium. In: Cohen PL (ed) Psychiatric consultation in childbirth settings. Plenum, New York, pp 165–206

    Google Scholar 

  53. Trixler M, Tenyi T (1997) Antipsychotic use in pregnancy. What are the best treatment options? Drug Saf 16:403–410

    PubMed  CAS  Google Scholar 

  54. Sacker A, Done DJ, Crow TJ (1996) Obstetric complications in children born to parents with schizophrenia: a meta analysis of case control studies. Psychol Med 26:279–287

    PubMed  CAS  Google Scholar 

  55. Bennedsen BE (1998) Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors. Schizophrenia Res 33:1–26

    CAS  Google Scholar 

  56. Desmond MM, Rudolph AJ, Hill RM (1969) Behavioural alterations and infants born to mothers on psychoactive medication during pregnancy. In: Farrell (ed) Congenital mental retardation. University of Texas Press, Austin, pp 235–244

  57. Hauser LA (1985) Pregnancy and psychotropic drugs. Hospital Commun Psychiatry 36:817–818

    CAS  Google Scholar 

  58. Falterman CG, Richardson C (1980) Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 97:308–310

    PubMed  CAS  Google Scholar 

  59. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A (2005) Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 66:444–449

    Article  PubMed  CAS  Google Scholar 

  60. Goldstein DJ, Corbin LA, Fung MC (2000) Olanzapine exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 20:399–403

    PubMed  CAS  Google Scholar 

  61. Gentile S (2004) Clinical utilisation of atypical antipsychotics in pregnancy and lactation. Ann Pharmacotherapy 38:1265–1271

    CAS  Google Scholar 

  62. Ernst C, Goldberg J (2002) The reproductive safety profile of mood stabilisers, atypical antipsychotics and broad spectrum psychotropics. J Clin Psychiatry 63(Suppl 4):42–55

    PubMed  CAS  Google Scholar 

  63. Cohen LS, Friedman J, Jefferson JW, Johnson EM, Weiner ML (1994) A re-evaluation of risk of in utero exposure to lithium. JAMA 271:146–150

    PubMed  CAS  Google Scholar 

  64. Nora JJ, Nora AH, Toews WH (1974) Lithium, Ebstein’s anomaly and other congenital heart defects. Lancet 2:594–595

    PubMed  CAS  Google Scholar 

  65. Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R (2002) Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 47:426–436

    PubMed  Google Scholar 

  66. Kallen B, Tandberg A (1983) Lithium and pregnancy: a cohort study on manic depressive women. Acta Psychiatrica 68:134–139

    CAS  Google Scholar 

  67. Mizrahi E, Hobbs J, Goldsmith D (1979) Nephrogenic diabetes insipidus in transplacental lithium intoxication. J Paediatr 94:493–495

    CAS  Google Scholar 

  68. Karlsson K, Lindstedt G, Lundberg P (1975) Transplacental lithium poisoning: reversible inhibition of foetal thyroid. Lancet 1:1295

    PubMed  CAS  Google Scholar 

  69. Llewellyn A, Stowe Z, Strader J (1998) The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 59(suppl 6):57–64

    PubMed  CAS  Google Scholar 

  70. Pinelli J, Symington A, Cunningham K, Paes BA (2002) Case report and review of the perinatal implications of maternal lithium use. Am J Obset Gynecol 187:245–249

    Google Scholar 

  71. Schou M (1976) What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 54:193–197

    PubMed  CAS  Google Scholar 

  72. Schou M (1998) Treating recurrent affective disorders during and after pregnancy. What can be taken safely? Drug Saf 18:143–152

    PubMed  CAS  Google Scholar 

  73. Williams K, Oke S (2000) Lithium and pregnancy. Drug Inf Quartery Psychiatric Bull 24:229–231

    Google Scholar 

  74. Robert E, Guibaud P (1982) Maternal valproic acid and congenital neural tube defects. Lancet 2:937

    PubMed  CAS  Google Scholar 

  75. Bjerkedal T, Czeizel A, Goujard J, Kallen B, Mastroiacova P, Nevin N, Oakley G Jr, Robert E (1982) Valproic acid and spina bifida. Lancet 2:1096

    PubMed  CAS  Google Scholar 

  76. Jager-Roman E, Deichl A, Jakob S, Hartmann AM, Koch S, Rating D, Steldinger R, Nau H, Helge H (1986) Fetal growth, major malformations and minor anomalies in infants born to women receiving valproic acid. J Pediatr 108:997–1004

    PubMed  CAS  Google Scholar 

  77. Briggs GG, Freeman RK, Yaffe SJ (1994) A reference guide to foetal and neonatal risk: drugs in pregnancy and lactation. Williams and Wilkins, Baltimore

    Google Scholar 

  78. Koch S, Jager-Roman E, Losche G, Nau H, Rating D, Helge H (1996) Anti-epileptic treatment in pregnancy: drug side-effects in neonates and neurological outcome. Acta Paediatrica 85:739–746

    PubMed  CAS  Google Scholar 

  79. Clayton-Smith J, Donnai D (1995) Foetal valproate syndrome. J Med Genetics 32:724–727

    CAS  Google Scholar 

  80. Paulson G, Paulson R (1981) Teratogenic effects of anticonvulsants. Arch Neurol 38:140–143

    PubMed  CAS  Google Scholar 

  81. Newport DJ, Fisher A, Graybeal S (2004) Psychopharmacology during pregnancy and lactation. In: Schatzberg AF, Nemeroff CB (eds) APA textbook of psychopharmacology, 3rd edn. American Psychiatric Press, Washington, pp 1109–1146

    Google Scholar 

  82. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ (1984) The fetal valproate syndrome. Am J Med Genet 19:473–481

    PubMed  CAS  Google Scholar 

  83. Winter R, Donnai D, Burn J, Tucker SM (1987) Fetal valproate syndrome: is there a recognisable phenotype? J Med Genet 24:692–695

    PubMed  CAS  Google Scholar 

  84. Mountain K, Hirsh J, Gallus A (1971) Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet 1(7641):265–268

    Google Scholar 

  85. Kennedy D, Koren G (1998) Valproic acid use in pregnancy: issues in treating women of reproductive age. J Psychiatry Neurosci 23:223–228

    PubMed  CAS  Google Scholar 

  86. Ebbesen F, Joergensen A, Hoseth E, Kaad PH, Moeller M, Holsteen V, Rix M (2000) Neonatal hypoglycaemia and withdrawal symptoms after exposure in utero to valproate. Arch Dis Child Fetal Neonatal Ed 83:F124–129

    PubMed  CAS  Google Scholar 

  87. Philbert A, Pedersen B, Dam M (1985) Concentration of valproate during pregnancy in the newborn and in breast milk. Acta Neurol Scand 72:460–463

    Article  PubMed  CAS  Google Scholar 

  88. Scolnik D, Nulman I Rovet J, Gladstone D, Czuchta D, Gardner HA, Gladstone R, Ashby P, Weksberg R, Einarson T (1994) Neurodevelopment of children exposed in utero to phenytoin and carbamazepine therapy. JAMA 271:767–770

    PubMed  CAS  Google Scholar 

  89. Matalon S, Schechtman S, Goldzweig G, Ornoy A (2002) The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 16:9–17

    PubMed  CAS  Google Scholar 

  90. Jones K, Lacro R, Johnson K, Adams J (1989) Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 320:1661–1666

    Article  PubMed  CAS  Google Scholar 

  91. Yonkers K, Wisner K, Stowe Z, Leibenluft E, Cohen L, Miller L, Manber R, Viguera A, Suppes T, Altshuler L (2004) Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 161:608–620

    PubMed  Google Scholar 

  92. Dolovich L, Addis A, Vaillancourt J, Power JD, Koren G, Einarson TR (1998) Benzodiazepine use in pregnancy and major malformations or oral cleft: a meta-analysis of cohort and case control studies. BMJ 317:839–843

    PubMed  CAS  Google Scholar 

  93. Haram K (1977) Floppy infant syndrome and maternal diazepam. Lancet 2:612–613

    PubMed  CAS  Google Scholar 

  94. Miller L (1991) Clinical strategies for the use of psychotropic drugs during pregnancy. Psychiatr Med 9:275–298

    PubMed  CAS  Google Scholar 

  95. Rubin PC (1981) Current concepts: beta-blockers in pregnancy. New Engl J Med 305:1323–1326

    Article  PubMed  CAS  Google Scholar 

  96. American Academy of Pediatrics Committee on Drugs (1994) The transfer of drugs and other chemicals into human milk. Pediatrics 93:137–150

    Google Scholar 

  97. Nulman I, Ito S, Koren G (2003) Anti-depressant medication and breast-feeding. In: Steiner M, Koren G (eds) Handbook of female psychopharmacology. Martin Dunitz, London, pp 103–115

    Google Scholar 

  98. Fergusson DM, Beautrais AL, Silva PA (1982) Breast-feeding and cognitive development in the first seven years of life. Soc Sci Med 16:1705–1708

    PubMed  CAS  Google Scholar 

  99. Lucas A, Morley R, Cole TJ, Lister G, Leeson-Payne C (1992) Breast milk and subsequent intelligence quotient in children born pre-term. Lancet 339:261–264

    PubMed  CAS  Google Scholar 

  100. Chaudron LH, Jefferson JW (2000) Mood stabilisers during breast-feeding: a review. J Clin Psychiatry 61:79–90

    Article  PubMed  CAS  Google Scholar 

  101. Llewellyn A, Stowe ZN (1998) Psychotropic medications in lactation. J Clin Psychiatry 59(suppl2):41–52

    PubMed  Google Scholar 

  102. Mortola JF (1989) The use of psychotropic agents in pregnancy and lactation. Women’s Disorders 12:69–87

    CAS  Google Scholar 

  103. Buist A, Norman TR, Dennerstein L (1990) Breast-feeding and the use of psychotropic medication: a review. J Affect Disord 19:197–206

    PubMed  CAS  Google Scholar 

  104. Suri RA, Altshuler LL, Burt VK, Hendrick VC (1998) Managing psychiatric medications in the breast-feeding woman. Medscape Womens Health 3:1–10

    PubMed  CAS  Google Scholar 

  105. Pons G, Rey E, Matheson I (1994) Excretion of psychoactive drugs into breast milk: pharmacokinetic principles and recommendations. Clin Pharmacokinet 27:270–289

    PubMed  CAS  Google Scholar 

  106. Kohen D (2005) Psychotropic medication and breast feeding. Adv Psychiatric Treatment 11:371–379

    Google Scholar 

  107. Atkinson HC, Begg EJ, Darlow BA (1988) Drugs in human milk: clinical pharmacokinetic considerations. Clin Pharmacokinet 14:217–240

    PubMed  CAS  Google Scholar 

  108. Atkinson AJ Jr, Stec GP, Lertora JJ, Ruo TI, Thenot JP (1980) Impact of active metabolites on monitoring plasma concentrations of therapeutic drugs. Ther Drug Monit 2:19–27

    Article  PubMed  CAS  Google Scholar 

  109. Morselli PL, Franco-Morselli R, Bossi L (1980) Clinical pharmacokinetics in newborns and infants: age related differences and therapeutic implications. Clin Pharmacokinet 5:485–527

    PubMed  CAS  Google Scholar 

  110. Morselli PL (1976) Clinical pharmacokinetics in neonates. Clin Pharmacokinet 1:81–98

    PubMed  CAS  Google Scholar 

  111. Wisner KL, Perel JM (1996) Nortriptyline treatment of breast-feeding women. Am J Psychiatry 153:295

    PubMed  CAS  Google Scholar 

  112. Bennett PN (1996) Use of the monographs on drugs. In: Bennett PN (ed) Drugs and human lactation. Elsevier, Amsterdam, pp 67–74

    Google Scholar 

  113. Bader TF, Newman K (1980) Amitryptyline in human breast milk and nursing infants’ serum. Am J Psychiatry 137:855–856

    PubMed  CAS  Google Scholar 

  114. Stancer HC, Reed KL (1986) Desipramine and 2-hydroxydesipramine in human breast milk and the nursing infant’s serum. Am J Psychiatry 143:1597–1600

    PubMed  CAS  Google Scholar 

  115. Schimmell MS, Katz EZ, Shaag Y, Pastuszak A, Koren G (1991) Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 29:479–484

    Article  PubMed  CAS  Google Scholar 

  116. Wisner KL, Perel JM (1991) Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry 148:1234–1236

    PubMed  CAS  Google Scholar 

  117. Matheson I, Panda H, Alertsen AR (1985) Respiratory depression caused by N-desmethyldoxepin in breast milk. Lancet 2:1124

    PubMed  CAS  Google Scholar 

  118. Yoshida K, Smith B, Craggs M, Kumar RC (1998) Fluoxetine in breast milk and development outcome of breast-fed infants. Br J Psychiatry 172:175–178

    PubMed  CAS  Google Scholar 

  119. Hale TW, Shum S, Grossberg M (2001) Fluoxetine toxicity in a breast-fed infant. Clin Paediatrics 40:681–684

    CAS  Google Scholar 

  120. Misri S, Kim J, Riggs KW, Kostaras X (2000) Paroxetine levels in postpartum depressed women, breast milk and infant serum. J Clin Psychiatry 61:828–832

    Article  PubMed  CAS  Google Scholar 

  121. Duncan D, Taylor D (1995) Which anti-depressants are safe to use in breast-feeding mothers? Psychiatric Bull 19:551–552

    Google Scholar 

  122. Merlob P, Stahl B, Sulkes J (2004) Paroxetine during breast feeding: infant weight gain and maternal adherence to counsel. Eur J Paediatr 163:135–139

    CAS  Google Scholar 

  123. Altshuler LL, Burt VK, McMullen M, Hendrick V (1995) Breast-feeding and sertraline: a 24 hour analysis. J Clin Psychiatry 56:243–245

    PubMed  CAS  Google Scholar 

  124. Stowe ZN, Owens MJ, Landry JC, Kilts CD, Ely T, Llewellyn A, Nemeroff CB (1997) Sertraline and desmethyl sertraline in human breast milk and nursing infants. Am J Psychiatry 154:1255–1260

    PubMed  CAS  Google Scholar 

  125. Weissman A, Levy B, Hartz A, Bentler S, Donohue M, Ellingrod VL, Wisner KL (2004) Pooled analysis of antidepressant levels in lactating mothers, breast milk and nursing infants. Am J Psychiatry 161:1066–1078

    PubMed  Google Scholar 

  126. Jensen PN, Olesen OV, Bertelsen A, Linnet K (1997) Citalopram and desmethylcitalopram concentration in breastmilk and serum of mother and infant. Therapeutic Drug Monitoring 19:236–239

    PubMed  CAS  Google Scholar 

  127. Spigset O, Carleborg L, Ohman R, Norstrom A (1997) Excretion of citalopram in breast milk. Br J Clin Pharmacol 44:295–298

    PubMed  CAS  Google Scholar 

  128. Lee A, Woo J, Ito S (2004) Frequency of infant adverse effects that are associated with citalopram use during breast-feeding. Am J Obstet Gynaecol 190:218–221

    CAS  Google Scholar 

  129. Ilett KF, Hacket LP, Dusci LJ, Roberts MJ, Kristensen JH, Paech M, Groves A, Yapp P (1998) Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 45:459–462

    PubMed  CAS  Google Scholar 

  130. Yoshida K, Smith B, Craggs M, Kumar R (1997) Neuroleptic drugs in breast milk: a study of pharmacokinetics and possible adverse effects in breast-fed infants. Psychol Med 28:81–91

    Google Scholar 

  131. Whalley LJ, Blain PG, Prime JK (1981) Haloperidol secreted in breast milk. BMJ 282:1746–1747

    PubMed  CAS  Google Scholar 

  132. Gardiner SJ, Kristensen JH, Begg EJ, Hackett LP, Wilson DA, Ilett KF, Kohan R, Rampono J (2003) Transfer of olanzapine into breast milk, calculation of infant drug dose and effect on breast fed infants. Am J Psychiatry 160:1428–1431

    PubMed  Google Scholar 

  133. Illett KF, Hackett LP, Kristensen JH, Vaddadi KS, Gardiner SJ, Begg EJ (2004) Transfer of risperidone and 9-hydroxyrisperidone into human milk. Ann Pharmacotherapy 38:273–276

    Google Scholar 

  134. Lee A, Giesbrecht E, Dunn E, Ito S (2004) Excretion of quetiapine in breast milk. Am J Psychiatry 161:1715–1716

    PubMed  Google Scholar 

  135. Dev V, Krupp P (1995) Adverse event profile and safety of clozapine. Rev Contemporary Pharmacotherapy 6:197–208

    CAS  Google Scholar 

  136. American Academy of Pediatrics Committee on Drugs (2001) The transfer of drugs and other chemicals into human milk. Pediatrics 108:776–789

    Google Scholar 

  137. Yoshida K, Smith B, Kumar RC (1999) Psychotropic drugs in mothers’ milk: a comprehensive review of assay methods, pharmacokinetics and safety of breast feeding. J Psychopharmacol 13:64–80

    PubMed  CAS  Google Scholar 

  138. Merlob P, Mor M, Litvin A (1992) Transient hepatic dysfunction in an infant of an epileptic mother treated with carbamazepine during pregnancy and breastfeeding. Ann Pharmacotherapy 26:1563–1565

    CAS  Google Scholar 

  139. Nau H, Rating D, Koch S, Hauser I, Helge H (1981) Valproic acid and its metabolite: placental transfer, neonatal pharmacokinetics, transfer via mother’s milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Therapeutics 219:768–777

    CAS  Google Scholar 

  140. Piontek C, Baab S, Peindl KS, Wisner KL (2000) Serum valproate levels in 6 breast-feeding mother-infant pairs. J Clin Psychiatry 61:170–172

    Article  PubMed  CAS  Google Scholar 

  141. Sivertz K (2005) The use of psychotropic medication in pregnancy and lactation. BC Med J 47:135–138

    Google Scholar 

  142. Birnbaum CS, Cohen LS, Bailey JW, Grush LR, Robertson LM, Stowe ZN (1999) Serum concentration of antidepressants and benzodiazepines in nursing infants: a case series. Paediatrics 104:e11

    CAS  Google Scholar 

  143. Matheson I, Sande HA, Gaillot J (1990) The excretion of zopiclone into breast milk. Br J Clin Pharmacol 30:267–271

    PubMed  CAS  Google Scholar 

  144. Bazire S (2003) Psychotropic drug directory. Fivepin Publishing, Salisbury

    Google Scholar 

Download references

Acknowledgments

I wish to thank Dr Brian Harris, Consultant Psychiatrist, BUPA Hospital Cardiff, United Kingdom for his invaluable support and guidance during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Royal Glamorgan Hospital, Pontypridd & Rhondda NHS Trust, Llantrisant, CF72 8XR, UK

    Sharmila J. Menon

Authors
  1. Sharmila J. Menon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sharmila J. Menon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Menon, S.J. Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet 277, 1–13 (2008). https://doi.org/10.1007/s00404-007-0433-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-007-0433-2

Keywords

Search

Navigation